Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 21, 2020− Dr. Shacham Recognized for Her Contributions to Science and Inspiring Others with Her Vision, Leadership and Achievement
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, congratulates its founder, President and Chief Scientific Officer, Sharon...
-
Aug 4, 2020-- Second Quarter 2020 XPOVIO Net Product Sales of $18.6 Million; Strongest Quarterly Sales Since July 2019 Launch --
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended June 30, 2020. In...
-
Aug 3, 2020
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options...
-
Jul 28, 2020− Conference Call Scheduled for Tuesday, August 4, 2020, at 8:30 a.m. ET −
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) an innovation-driven pharmaceutical company, today announced that it will report second quarter 2020 financial results on Tuesday, August 4, 2020....
-
Jul 20, 2020
NEWTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration...
-
Jul 1, 2020
NEWTON, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of...
-
Jun 24, 2020
NEWTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL...
-
Jun 22, 2020-- XPOVIO is Now the Only Single-Agent, Oral Therapy Approved for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Including DLBCL Arising from Follicular Lymphoma --
NEWTON, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration...
-
Jun 12, 2020-- Selinexor Demonstrates a Significant Survival Benefit in Patients with Relapsed or Refractory DLBCL and Durable Responses in Important DLBCL Patient Subgroups, Including Those with Primary Refractory Disease and Regardless of Number of Prior Therapies --
NEWTON, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that eight posters relating to XPOVIO®...
-
Jun 9, 2020
NEWTON, Mass., June 09, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Phase 1/2...
-
Jun 1, 2020
NEWTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of...
-
May 28, 2020-- Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) and Dexamethasone (SVd) Prolonged Median Progression-Free Survival by 47% Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd) --
NEWTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today reported detailed results from the pivotal, Phase 3...
-
May 26, 2020-- Fireside Chat Scheduled for Tuesday, June 2, 2020, at 9:30 a.m. ET --
NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
May 26, 2020-- Fireside Chat Scheduled for Tuesday, June 2, 2020, at 9:30 a.m. ET --
NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
May 20, 2020
NEWTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced it has submitted a supplemental New Drug...
-
May 13, 2020
NEWTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute...
-
May 12, 2020Fireside Chat Scheduled for Tuesday, May 19, 2020, at 8:35 a.m. ET
NEWTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
May 5, 2020-- Pivotal Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival; Oral Presentation at ASCO 2020 Virtual Scientific Program and sNDA To Be Submitted by End of May 2020 --
NEWTON, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today reported financial results for the quarter ended...
-
May 1, 2020
NEWTON, Mass., May 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of...
-
Apr 29, 2020- A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study -
NEWTON, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that its late-breaking abstract detailing...
-
Apr 28, 2020-- Conference Call Scheduled for Tuesday, May 5, 2020, at 8:30 a.m. ET --
NEWTON, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it will report first quarter 2020 financial results on Tuesday, May 5, 2020....
-
Apr 20, 2020
NEWTON, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose...
-
Apr 7, 2020− Company to Initiate a Global Randomized Clinical Trial to Treat Patients with COVID-19 −
NEWTON, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced plans to initiate a global randomized clinical trial for low dose oral selinexor in...
-
Apr 1, 2020
NEWTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
-
Mar 17, 2020
NEWTON, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
-
Mar 12, 2020
NEWTON, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of John Demaree as Chief...
-
Mar 9, 2020
NEWTON, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
-
Mar 6, 2020
NEWTON, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the closing of its previously announced...
-
Mar 3, 2020− Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) plus Dexamethasone (SVd) Results in Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd) Regimen −
NEWTON, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced positive top-line results from the...
-
Mar 2, 2020− Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) plus Dexamethasone (SVd) Results in Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd) Regimen −
NEWTON, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced positive top-line results from the...
-
Mar 2, 2020
NEWTON, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered...
-
Feb 28, 2020Current Executive Vice President and Chief Executive Officer of Ipsen North America, and former Vice President and General Manager of Oncology at Amgen, Inc.; Brings Wealth of Leadership and Global Strategic Experience
NEWTON, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of Richard Paulson to its...
-
Feb 19, 2020Priority Review Granted; User Fee Goal Date Set for June 23, 2020
NEWTON, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA
-
Feb 18, 2020− Fireside Chat Scheduled for Tuesday, February 25, 2020, at 11:30 a.m. ET −
NEWTON, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Feb 13, 2020-- XPOVIO Net Product Sales of $17.7 Million for Fourth Quarter and $30.5 Million for Full Year 2019 --
NEWTON, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today reported financial results for the fourth quarter and...
-
Feb 11, 2020
NEWTON, Mass. and PETAH TIKVA, Israel, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, and Promedico, a member of the...
-
Feb 6, 2020Conference Call Scheduled for Thursday, February 13, 2020, at 8:30 a.m. ET
NEWTON, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report fourth quarter and full...
-
Feb 3, 2020
NEWTON, Mass., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
-
Jan 13, 2020-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 --
NEWTON, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced preliminary unaudited fourth quarter and...
-
Jan 7, 2020
NEWTON, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Jan 2, 2020
NEWTON, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
-
Dec 23, 2019
NEWTON, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application...
-
Dec 8, 2019-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma --
NEWTON, Mass., Dec. 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that four posters relating to XPOVIO®...
-
Dec 7, 2019-- All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst® and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst®-Naïve and Revlimid®-Relapsed or -Refractory Myeloma with Progression-Free Survival of 12.2 Months --
NEWTON, Mass., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that two presentations highlighting new and...
-
Dec 2, 2019
NEWTON, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
-
Nov 6, 2019-- Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple Myeloma to be Highlighted --
NEWTON, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that thirteen abstracts have been selected...
-
Nov 4, 2019− XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine −
NEWTON, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today reported financial results for the third quarter...
-
Nov 1, 2019
NEWTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
-
Oct 28, 2019-- Conference Call Scheduled for Monday, November 4, 2019 at 8:30 a.m. ET --
NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report third quarter 2019...
-
Oct 1, 2019
NEWTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...